The binding performance of DFE Pharma Starch
|
|
- Calvin Miller
- 6 years ago
- Views:
Transcription
1 The binding performance of DFE Pharma Starch MCC Starch Lactose Inhalation Superdisintegrants
2 We are DFE Pharma We are the global leader in excipient solutions. We develop, produce and market excipients for oral solid dose and dry powder inhalation formulations. Our customers are pharmaceutical companies, operating globally, regionally and locally. The pursuit of excipient excellence Excipient excellence is a pursuit that will never be fully achieved. What is excellent today will be outdated tomorrow. That s why to us the pursuit of excipient excellence is a way of life. A source of inspiration. Excipient excellence is what guides us on our way to developing and producing the best possible excipient solutions for our customers. Today, tomorrow, always. Leading in expertise We are here to help you create pharmaceutical products that set the new standard. Leading in supply We are here to ensure you can always produce your products. No matter what happens. Leading in time to market We are here to help you grow by minimising the time to market. We invite you to join us in our pursuit of excipient excellence. Pursuit the act of striving towards an ideal with strong determination.
3 3 Starch Your Starch by DFE Pharma Starches have a proven track record as effective excipients. Together with our solid experience with excipients, we provide this natural product in our excipients product portfolio. Which means you can also use starch s binding performance. Brought to you by DFE Pharma. Starch and starch derivatives are widely used excipients in the pharmaceutical industry and are frequently used in oral solid dosage forms such as tablets, capsules or sachets. Our in-house knowledge of starch enables us to provide high-level support and innovative solutions to specific customer challenges. Our production process and your pharmaceutical end product are important factors that determine the appropriate type of starch to be used in the formulation. For many years numerous pharmaceutical companies have successfully formulated their solid oral dosage forms using our native and pregelatinised starch products. DFE Pharma offers three reliable pharmaceutical-grade starch products: Solani Amylum: native potato starch Prejel PA5 PH: fully pregelatinised potato starch SuperStarch 2: partly pregelatinised starch
4 4 Solani Amylum Native potato starch Description Solani Amylum is a purified potato starch in the form of a white and free flowing powder. Solani Amylum complies with USP NF, Ph. Eur. and JP monographs for native (potato) starch (Figure 1, top). Potato starch is a widely accepted raw material within the pharmaceutical market. In comparison to other starches it has a low protein and fat content. Potato starch is also gluten free and Solani Amylum can be provided with a GMO-free statement. Applications Solani Amylum is an excipient often used as filler in hard gelatin capsule formulations. This is commonly done in a blend with partly pregelatinised starch. In this application the necessary cohesiveness for plug formation at light tamping forces together with plug dispersion and drug release is readily achieved. Solani Amylum is also used as a disintegrant in tablets at levels of about 5% to 2% (Figure 2). When cooked up to a paste, Solani Amylum can be used as a binder in wet granulation applications. Figure 1 (bottom) shows the typical viscosity profile of cooked up Solani Amylum solution. Specification Moisture content < 2% ph Oxidising substances <.2% Sulphur dioxide < 5 ppm Iron < 1 ppm Total aerobic mesophilic count < 1 cfu/g Yeasts and moulds < 1 cfu/g E. coli (1g) Absent Salmonella (25g) Absent Label Declaration Solani Amylum Potato Starch USP-NF, Ph. Eur., JP. Packaging Multilayer 25kg white paper bag with polyethylene coating. Storage Store the product in well sealed bags, inside a cool and dry place. It is advised however, to keep the storage as short as possible to avoid gradually increasing moisture content. Viscosity (mpas) Disintegration time (sec) % 2% 4% 6% 8% 1% 12% 14% 16% Solids 5 kn 1 kn 15 kn Solani Amylum Prejel PA5 PH SuperTab11SD/1M (75:25) 1% SuperTab11SD/MCC12 (75:25) 1% Figure 1: Photomicrograph of granules of potato starch under polarised light (upper image) viscosity profile of native potato starch compared to fully pregelatinised potato starch (lower image). Figure 2: Disintegration time (in sec) of tablets compressed with 1% starch content with SuperTab 11SD/Pharmatose 1M and SuperTab 11SD/Pharmacel 12.
5 5 Prejel PA5 PH Fully pregelatinised potato starch Description Prejel PA5 PH is a cold water swelling fully pregelatinised potato starch in the form of a white, free flowing powder (figure 3). Prejel PA5 PH complies with USP NF and Ph. Eur. and JP monographs for pregelatinised starch. Prejel PA5 PH is also gluten free and can be provided with a GMOfree statement. Gelatinisation Gelatinisation is the collapse (disruption) of molecular orders within the starch granule where irreversible changes in properties occur such as granular swelling, crystallite melting, loss of birefringence, viscosity development, and starch solubilisation. The latter is especially important as the soluble content is high, which makes it very suitable as a binder. Applications Therefore, Prejel PA5 PH is widely used in oral solid dosage forms such as tablets. In wet granulation formulations Prejel PA5 PH can be added to the granulation liquid or to the dry blend. Prejel PA5 PH removes the costs of creating a starch paste while maintaining viscosity and providing extra flowability compared to Solani Amylum. As a binder used in wet granulation Prejel PA5 PH increases the hardness of a tablet and decreases its friability. Figure 4 shows how cost effective Prejel PA5 PH is as a binder compared to a synthetic polymer such as PVP. Specification Moisture content < 13% ph Sieve analysis >92% on 125 μm Oxidising substances negative Sulphur dioxide <.5% Iron (Fe) < 2ppm Total aerobic microbial count < 1 cfu/g Total yeasts and moulds < 1 cfu/g E. coli (1g) Absent Salmonella (25g) Absent Label Declaration Prejel PA5 PH Pregelatinised potato starch USP-NF, Ph. Eur., JP. Packaging Multilayer 25kg white paper bag with polyethylene coating. Storage Store well sealed bags, inside a cool and dry place. It is advised however, to keep the storage as short as possible to avoid gradually increasing moisture content. Prejel PA5 PH is especially suitable for dry addition in wet granulation because it reduces overwetting problems. crushing strength (N) Prejel PSS PVP Prejel PSS PVP Prejel PSS PVP Water.5% solution 2% dry addition 4% dry addition Figure 3: Photomicrograph of fully pregelatinised potato starch granules (Prejel PA 5 PH). Figure 4: Effect of different concentrations of binders (water, fully pregelatinised starch (Prejel), partially pregelatinised starch (PSS) and synthetic polymer (PVP)) in wet (5% binder solution, dry substance.5%) and dry state (1% water is used to moisten mass) using lactose (Pharmatose 2M) as filler.
6 6 SuperStarch 2 Partly pregelatinised starch Description SuperStarch 2 is a partly pregelatinised maize starch that integrates multiple functionalities including binder, diluent and disintegrant. SuperStarch 2 complies with all tests in major pharmacopoeia. The main application areas of SuperStarch 2 include tablets and capsules prepared by both direct compression/ blending and by wet granulation. SuperStarch 2 is produced by a mechanical gelatinisation process. Figure 6 shows SuperStarch 2 to be a combination of agglomerated particles and loose starch grains. Under polarised light (figure 7) the mixture of birefringent and nonbirefringent starch particles is seen confirming the partial pregelatinisation. SuperStarch 2 maintains low water activity compared to other common excipients (figure 8, left). Water sorption is completely reversible, as shown by the DVS cycle (figure 8, right). SuperStarch 2 contains both native and ruptured maize starch grains. Ruptured grains provide the soluble component, which is responsible for the binding properties in wet granulation. The native starch grains, a mixture of amylopectin and amylose (figure 5, approximately 73 and 27% respectively), are responsible for the disintegra ting properties of SuperStarch 2. Amylose Amylopectin Figure 6: Scanning electron photomicrograph of partially pregelatinised maize starch granules (SuperStarch 2) at 5X magnification. Figure 7: Photomicrograph (1X) of SuperStarch 2 under polarized light. Figure 5: Depicts the building blocks of maize starch as amylose (27%) and amylopectin (73%). Amylose provides the binding force while amylopectin helps in disintegration by swelling. Loss on drying (%) Water activity (-) Change in Mass (%) - Dry Competitor P-PGS SuperStarch 2 Microcrystalline cellulose DCP Anhydrous Anhydrous lactose Loss on drying (%) Water activity DCP Dihydrate Milled lactose % relative humidity Sorption 1 Desorption 1 Sorption 2 Desorption 2 Figure 8: Loss on drying and water activity of SuperStarch 2 versus other commonly used excipients (left) dynamic vapor sorption isotherm of SuperStarch 2 (double cycle).
7 7 Applications The combination of native and gelatinised starch particles allows SuperStarch 2 to act in a formulation as both binder as a disintegrant. In direct compression applications, SuperStarch 2 is best used in combination with other typical DC excipients, both soluble and non-soluble, such as direct compression lactose or microcrystalline cellulose (figures 9 and 1). A typical usage rate is in the range of 1-5 w/w %. In wet granulation, SuperStarch 2 acts both as a binder and a disintegrant. A typical usage rate is in the range of 5-25 w/w %. SuperStarch 2 is also a very effective excipient for simple direct blend formulations for encapsulation. It helps to form cohesive plugs that transfer cleanly into capsule shells, therefore helping to minimise dust formation during capsule filling. Specification SuperStarch 2 Min. Max. Cold water solubles (%) 1 2 Particle size specifications <53 um sieve (%) 25 1 <15 um sieve (%) 9 1 <425 um sieve (%) Residue on Ignition (%).5 Oxidising substances Negative ph Sulphur dioxide (ppm) 3 Loss on drying (%) 13 Typically measured and derived properties Typical poured density (g/ml).64 Typical tapped density (g/ml).8 Typical Hausner ratio 1.25 Typical Carr s Compressibility Index (%) 2 Typical Color Off white Packaging SuperStarch 2 is available in 25kg multilayer paper bags with a polyethylene inner liner. Storage Store well sealed bags, inside a cool and dry place. It is advised however, to keep the storage as short as possible to avoid gradually increasing moisture content. Disintegration time (sec) % drug released Tablet hardness (N) SD lactose/superstarch 2 (9:1) SD lactose/competitor P-PGS (9:1) MCC/SuperStarch 2 (5:5) MCC/Competitor P-PGS (5:5) Time (min) DC-SuperStarch 2 DC-Competitor P-PGS WG-SuperStarch 2 WG-Competitor P-PGS Figure 9: Disintegration time profile Vs. hardness for SuperStarch 2 in combination with MCC or spray-dried lactose in 25 mg placebo tablets. Figure 1: Comparative dissolution profile of medium dose (5mg) API in 2 mg wet granulated and directly compressed tablet composed of Superstarch 2 and Pharmacel 11.
8 Head Office Klever Strasse 187 P.O. Box Goch Germany T F pharma@dfepharma.com North America 61 South Paramus Road Suite 535 Paramus, NJ 7652 USA T F Japan Kudan Vigas Bldg 3F Kudan-Kita Chiyoda-Ku Tokyo 12-73, Japan T F Singapore 3 Temasek Avenue #11-1 Centennial Tower Singapore 3919 T F India Plot No. 148, Prestige Featherlite Tech Park 2nd Phase, EPIP Zone Whitefield, Bangalore 5666 India T F China Room 119, #1 Building No 2277 Zuchongzhi Road, 2123 Pudong Shanghai China T. +86 () F. +86 () Brazil Rua dos Canarios, 65 Vinhedo, Sao Paulo , Brazil DFE Pharma (#4/November 214) DMV-Fonterra Excipients GmbH & Co. KG - Warranty The details given here are merely intended for information purposes and are in no way legally binding. Consequently we accept no responsibility in the broadest sense of the word for damage that may result from applications based upon this information. Furthermore, this information does not constitute permission to infringe patent and licence rights.
YOUR ORAL SOLID DOSE. In pursuit of excipient excellence
YOUR ORAL SOLID DOSE DFE Pharma globally supplies a unique, broad portfolio of key excipients including lactose, MCC, superdisintegrants and starches. Innovative products such as SuperTab 24AN and SuperTab
More informationThe unlocked synergy of DFE Pharma MCC
The unlocked synergy of DFE Pharma MCC We are DFE Pharma We are the global leader in excipient solutions. We develop, produce and market excipients for oral solid dose and dry powder inhalation formulations.
More informationSTARCH Proven and Trusted Excipient for Performance and Versatility EXCIPIENTS. Effective and economical disintegrant
EXCIPIENTS STARCH 1500 Proven and Trusted Excipient for Performance and Versatility Effective and economical disintegrant Excellent stability for moisture sensitive drugs Manufactured exclusively for the
More informationTechnical brochure StarLac
T R TABLETING AC DIRECT COMPRESSION CO-PROCESSED LACTOSE Technical brochure MEGGLE co-processed lactose grades for direct compression: General information Direct compression (DC) tablet manufacture is
More informationOCE TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE. Technical brochure MicroceLac 100
IC OCE TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE AC Technical brochure MEGGLE co-processed lactose grades for direct compression: General information Direct compression (DC) tablet manufacture
More informationFLORITER. New Technology for Innovative Formulation Design.
FLORITER New Technology for Innovative Formulation Design www.tomitaph.co.jp FLORITE Dramatically Change Your Formulation FLORITE is synthetic Calcium Silicate with exceptional liquid absorbency and excellent
More informationTechnical brochure CombiLac
OM I AC TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE Technical brochure MEGGLE co-processed lactose grades for direct compression: General information Direct compression (DC) tablet manufacture is
More informationApplication of Starches, Modified Starches and Starch Derivatives in Pharmaceutical Products
57. Starch Convention, Detmold, April 26-28, 2006 K.-J. Steffens Application of Starches, Modified Starches and Starch Derivatives in Pharmaceutical Products Starches, Pharmaceutical Applications _ Starches
More informationDesigned and manufactured specifically for pharmaceutical capsule filling
EXCIPIENTS Designed and manufactured specifically for pharmaceutical capsule filling Simple formulation Superior flow and weight uniformity Clean and efficient processing This document is valid at the
More informationSTARCH Application Data
STARCH 1500 Application Data Partially Pregelatinized Maize Starch Starch 1500, Partially Pregelatinized Maize Starch, Used as a Binder Disintegrant in High Shear Wet Granulation Comparison to Povidone
More informationCo-Processed Excipients: Regulatory Challenges. Carl Mroz Colorcon Limited June 2009
Co-Processed Excipients: Regulatory Challenges Carl Mroz Colorcon Limited June 2009 What is a Co-Processed excipient? Several types of excipient contain multiple components by design Use of processing
More informationRe-compaction properties of lactose and microcrystalline cellulose
Re-compaction properties of lactose and microcrystalline cellulose Individual excipients MCC Starch Lactose Inhalation Superdisintegrants SuperTab 21AN (anhydrous lactose) is the preferred form of lactose
More informationVIVAPHARM PVP/VA. Copovidone, Ph.Eur. USP/NF, JPE, E. The Ultimate Tablet Binder for All Processing Technologies
VIVAPHARM PVP/VA Copovidone, Ph.Eur. USP/NF, JPE, E 1208, FCC The Ultimate Tablet Binder for All Processing Technologies Direct Compression Dry Granulation Hot Melt Extrusion Wet Granulation VIVAPHARM
More informationLubriTose Mannitol Michael Crowley, Director of R&D, Excipients
LubriTose Mannitol Michael Crowley, Director of R&D, Excipients Introduction Michael Crowley Director of R&D Excipients 158 St. Highway 320 Norwich, NY 13815 PH 315-802-5970 Michael.Crowley@Kerry.com 2
More informationCONTENTS PAGE. Please note: Preface Matrix system Selection of METOLOSE grades Specifications
Hypromellose CONTENTS PAGE 2 Preface Matrix system Selection of METOLOSE grades Specifications Properties Powder Solution Application Related Patents 3 4-5 6 8 10 13 14 17 Please note: The information
More informationREVISION OF MONOGRAPH ON TABLETS. Tablets
March 2011 REVISION OF MONOGRAPH ON TABLETS Final text for addition to The International Pharmacopoeia This monograph was adopted by the Forty-fourth WHO Expert Committee on Specifications for Pharmaceutical
More informationFormulation and Evaluation
Chapter-5 Formulation and Evaluation 5.1 OBJECTIVE After successful taste masking and solubility enhancement of drugs in preliminary studies, by using Mannitol Solid Dispersion, next step includes the
More informationPrimellose is an excellent choice as superdisintegrant in ODT applications
Primellose is an excellent choice as superdisintegrant in ODT applications MCC Starch Lactose Inhalation Superdisintegrants Summary In orally disintegrating tablets, the excipients of choice in direct
More informationTECHNICAL INFORMATION RxCIPIENTS FM A versatile excipient for orally disintegrating tablet (ODT) formulations
TECHNICAL INFORMATION 1426 RxCIPIENTS FM 1 A versatile excipient for orally disintegrating tablet (ODT) formulations Table of contents 1 Introduction 3 2 Mode of action and advantages of RxCIPIENTS FM
More informationEUDRAGIT E 100, EUDRAGIT E PO and
Technical Information EUDRAGIT E 100, and Specification and Test Methods Ph. Eur. USP/NF JPE Basic Butylated Methacrylate Copolymer Amino Methacrylate Copolymer - NF Aminoalkyl Methacrylate Copolymer E
More informationLactose Free, Direct Compression Formulation Used to Produce Loratadine (10 mg) Tablets
Technical Data Direct Compression Loratadine Formulation Lactose Free, Direct Compression Formulation Used to Produce Loratadine (10 mg) Tablets INTRODUCTION Loratadine is a popular over-the-counter, nonsedating
More informationContent Uniformity of Direct Compression tablets
Content Uniformity of Direct Compression tablets Contents 1 Summary 4 2 Introduction 4 3 The role of drug particle size 4 4 The role of mixing strategy 5 5 The role of excipients 5 6 Laboratory data 6
More informationEasy, fast and reliable!
Product Overview Easy, fast and reliable! Special easy-to-use preparations for film coating, sugar-coating, colouring and tabletting. Tailormade formulated. s film coating products are one-step coating
More informationEUDRAGIT L 100 and EUDRAGIT S 100
Technical Information EUDRAGIT L 100 and EUDRAGIT S 100 Specification and Test Methods Ph. Eur. Methacrylic Acid - Methyl Methacrylate Copolymer (1:1) Methacrylic Acid - Methyl Methacrylate Copolymer (1:2)
More informationFAO SPECIFICATIONS FAO PLANT PROTECTION PRODUCTS SULPHUR. FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS Rome, 1973
AGP: CP/58 FAO SPECIFICATIONS FAO PLANT PROTECTION PRODUCTS SULPHUR FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS Rome, 1973 DISCLAIMER 1 FAO specifications are developed with the basic objective
More informationDirect Compression Formulation Using Starch 1500 with Ranitidine HCl (150 mg) Tablets, Film Coated with Opadry II (85F Series)
Technical Data Direct Compression Ranitidine Formulation Direct Compression Formulation Using Starch 15 with Ranitidine HCl (15 mg) Tablets, Film Coated with Opadry II (5F Series) INTRODUCTION Ranitidine
More informationDevelopment of USP Delayed Release Aspirin Tablets using Opadry Enteric, Acrylic-Based Coating System
Opadry Enteric Application Data Acrylic-Based Coating System Development of USP Delayed Release Aspirin Tablets using Opadry Enteric, Acrylic-Based Coating System INTRODUCTION Acetylsalicylic acid (aspirin)
More informationSUSTAINED RELEASE TABLETS USING A PVA DC FORMULATION RESISTANT TO ALCOHOL INDUCED DOSE DUMPING
SUSTAINED RELEASE TABLETS USING A PVA DC FORMULATION RESISTANT TO ALCOHOL INDUCED DOSE DUMPING Dr. Dieter Lubda MilliporeSigma is a business of Merck KGaA, Darmstadt, Germany Agenda: Sustained release
More informationDirect Compression. With the right ingredients it s a simple, cost-effective manufacturing process
Direct With the right ingredients it s a simple, cost-effective manufacturing process TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow Speed and savings sounds good to us
More informationDEVELOPMENT OF NON SODIUM EFFERVESCENT TABLET OF PARACETAMOL USING ARGININE CARBONATE
IJPSR (2013), Vol. 4, Issue 5 (Research Article) Received on 17 July, 2012; received in revised form, 23 February, 2013; accepted, 14 April, 2013 DEVELOPMENT OF NON SODIUM EFFERVESCENT TABLET OF PARACETAMOL
More information3. Drug or plant or excipients profile
3. Drug or plant or excipients profile 3. 1 Analysis of Reference Listed Drug (RLD) Product ABILIFY (aripiprazole) 3.1.1 Clinical The Reference Listed Drug (RLD) is Brand ABILIFY (aripiprazole) Tablets
More informationAvailable online through
Research Article Available online through www.ijrap.net DESIGN AND EVALUATION OF LOW COST DIRECTLY COMPRESSIBLE EXCIPIENTS Swamy P. V. *, Patil A. N., Shirsand S. B., Amitkumar T., Laeeq Farhana H.K.E
More informationAdopting Technologies to Enhance Quality in Manufacturing
Adopting Technologies to Enhance Quality in Manufacturing Sandip B. Tiwari, Ph.D. March 18, 2012 Current Status of Quality in Pharma Manufacturing Pharmaceutical manufacturing techniques lag behind those
More informationORAL DOSAGE OVERVIEW
ORAL DOSAGE OVERVIEW AN UNWAVERING COMMITMENT TO ENABLING LIFE-SAVING PHARMACEUTICALS The safety of your patients is your number one priority. That s why the quality and stability of your formulations
More informationC Gel Parameter Unit Min Typical Max Text
C Gel 03401 DESCRIPTION Native maize starch RAW MATERIAL Corn (Maize) PRODUCT LABEL Package labelling Ingredients [Listed in Descending Order] Maize starch Starch PRODUCT CLASSIFICATION CN Code (Valid
More informationFORMULATION CHOICE. How and why they are chosen. Dr Andy Fowles On behalf of ECPA Specification Expert Group
FORMULATION CHOICE How and why they are chosen Dr Andy Fowles On behalf of ECPA Specification Expert Group Topics Why formulate? How to identify formulation options Drivers Principle formulation type overview
More informationEffect of Compaction Forces on Powder Bed Permeability of Magnesium Silicate "Common Excipient Mixture"
Effect of Compaction Forces on Powder Bed Permeability of Magnesium Silicate "Common Excipient Mixture" SAMEER AL-ASHEH a, FAWZI BANAT a, ALA A SALEM a, IAD RASHID b, ADNAN BADWAN b a Department of Chemical
More informationAGP: CP/89 FAO SPECIFICATIONS FOR PLANT PROTECTION PRODUCTS. PHENTHOATE S - a - ethoxycarbonylbenzyl 00-dimethyl phosphorodithioate
AGP: CP/89 FAO SPECIFICATIONS FOR PLANT PROTECTION PRODUCTS PHENTHOATE S - a - ethoxycarbonylbenzyl 00-dimethyl phosphorodithioate FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS Rome, 1980 DISCLAIMER
More informationGuidance on Pharmaceutical Excipient Suitability Studies (PESS) with Chinese Pharmacopeia (Volume 4): Basics and Examples
Guidance on Pharmaceutical Excipient Suitability Studies (PESS) with Chinese Pharmacopeia (Volume 4): Basics and Examples Professor Jiasheng Tu, Ph. D. France 2018/09 content 1 Introduction 2 PESS guidance
More informationSTABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS
Int. J. Chem. Sci.: 8(1), 2010, 405-414 STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS V. L. NARASAIAH, T. KARTHIK KUMAR, D. SRINIVAS, K. SOWMYA, P. L. PRAVALLIKA and Sk. Md. MOBEEN
More informationMETOLOSE: CONTENTS PAGE
METOLOSE: CONTENTS PAGE 2 Preface What is Metolose Substitution types Specifications 1) Available grades & viscosity 2) Nomenclature 3) Packaging Characteristics of Metolose Properties of Metolose 1) Powder
More informationSENTRY TM POLYOX Water Soluble Resins
SENTRY TM POLYOX Water Soluble Resins Technical Information on Stability Introduction Key Points Antioxidants SENTRY POLYOX WSR resins consist of a family of high molecular weight polyethers with nominal
More informationEasy, fast and reliable!
Product Overview Easy, fast and reliable! Special easy-to-use preparations for film coating, sugar-coating, colouring and tabletting. s film coating products are one-step coating systems for pharmaceutical
More informationGLYCOLYS
ROQUETTE WORLDWIDE EUROPE FRANCE Roquette Frères Corporate Headquarters 62080 Lestrem cedex - France Telephone: + 33 3 21 63 36 00 Fax: + 33 3 21 63 38 50 FINLAND Roquette Nordica Oy PL 11 P.O.B FIN-02171
More informationKolliwax HCO. Technical Information. Hydrogenated castor oil powder for pharmaceutical use. = Registered trademark in many countries.
Technical Information Kolliwax HCO September 2015 03_150617e_00/Page 1 of 8 WF-No. 129938 = Registered trademark in many countries Hydrogenated castor oil powder for pharmaceutical use 03_150617e_00 September
More informationDISCIPLINE RECORD/ COURSE / SEMINAR DESCRIPTION
Universitatea de Medicină şi Farmacie Grigore T. Popa Iaşi Comisia pentru asigurarea calităţii DISCIPLINE RECORD/ COURSE / SEMINAR DESCRIPTION 1. Information about the program UNIVERSITY: GRIGORE T. POPA
More informationDissolution control of direct compression tablets in different test media using novel pregelatinized starch, Swelstar TM MX-1
Dissolution control of direct compression tablets in different test media using novel pregelatinized starch, Swelstar TM MX-1 ASAHI KASEI CHEMICALS CORPORATION CEOLUS R&D DEPARTMENT 1 CONTENTS General
More informationAnimal Health. Premixes Dietary Fibers. and Gels Solid. Dosage Forms. Liquids. Product Overview. Customize Your Formulation
Animal Health Product Overview Liquids and Gels Solid Dosage Forms Premixes Dietary Fibers Customize Your Formulation ANIMAL HEALTH Product Overview General Information Liquids and Gels Healthcare is essential
More informationInt. Res J Pharm. App Sci., 2014; 4(1):47-51 ISSN:
International Research Journal of Pharmaceutical and Applied Sciences (IRJPAS) Available online at www.irjpas.com Int. Res J Pharm. App Sci., 2014; 4(1):47-51 Research Article FORMULATION AND EVALUATION
More informationWherever life takes you BASF excipients for orally disintegrating tablets make medication easy
Wherever life takes you BASF excipients for orally disintegrating tablets make medication easy Dr. Philipp Hebestreit, an enabler in excipients Pharma Ingredients & Services. Welcome to more opportunities.
More informationLYCOAT. New solutions for Film Coating from Roquette. LYCOAT for quicker quality coating
LYCOAT New solutions for Film Coating from Roquette LYCOAT for quicker quality coating Roquette LYCOAT New solutions for Film Coating from Roquette LYCOAT New solutions for Film Coating Film coating, the
More informationInnovations in Design: NIA-West. Missy Lowery, MSc Head of Integrated Marketing Capsugel, now a Lonza company 11/13/2017
Innovations in Design: NIA-West Missy Lowery, MSc Head of Integrated Marketing Capsugel, now a Lonza company 11/13/2017 1 Innovations in Design: How Do You Stand Out? If all other competitors are the same
More informationCHAPTER 5: FORMULATION OF SOLID DOSAGE FORM (TABLET & CAPSULES) INTRODUCTION
CHAPTER 5: FORMULATION OF SOLID DOSAGE FORM (TABLET & CAPSULES) INTRODUCTION LEARNING OBJECTIVES The objectives of this unit are to: Understand the formulation of solid dosage form. Understand the characteristic
More informationFormulation and evaluation of immediate release salbutamol sulphate
5 Formulation, optimization and evaluation of immediate release layer of salbutamol sulphate Salbutamol is moderately selective beta (2)-receptor agonist similar in structure to terbutaline and widely
More informationPARTIALLY PREGELATINISED MAIZE STARCHES FOR ORAL SOLID DOSAGE FORMS
PARTIALLY PREGELATINISED MAIZE STARCHES FOR ORAL SOLID DOSAGE FORMS LYCATAB C Partially pregelatinised maize starch LYCATAB C - LM Low Moisture partially pregelatinised maize starch LYCATAB C Partially
More informationSCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationTechnical brochure InhaLac
N A DRY POWDER INHALATION SIEVED/MILLED/MICRONIZED LACTOSE AC Technical brochure MEGGLE s, milled and alpha-lactose monyhydrate for dry powder : General information The delivery of active pharmaceutical
More informationGranulation Aggregation
Granulation Aggregation Wet granulation Solvent granulation (crust granules) Binder granulation (sticked granules) Granulation liquid Water Water + alcohol mixture Macromolecular colloidal solution i.e.:
More informationSCIENTIFIC DISCUSSION. AkuriT-3 Tablets*
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
More informationPharma & Food Solutions. POLYOX TM Water Soluble Resins Combining Flexibility with Consistency
Pharma & Food Solutions POLYOX TM Water Soluble Resins Combining Flexibility with Consistency POLYOX 9-13 POLYOX 9-13 POLYOX * are nonionic poly (ethylene oxide) polymers that meet all the specifications
More informationAssessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy
Starch 1500 Application Data Partially Pregelatinized Maize Starch Assessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy OBJECTIVE To characterize
More informationFormulation Development and Evaluation of Atorvastatin Calcium Tablets using Co-Processed Excipients
Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 39, Pages: 217222 Research Article Formulation Development and Evaluation of Atorvastatin Calcium Tablets using CoProcessed Excipients
More informationFormulation and In-vitro Evaluation of Chewable Tablets of Montelukast Sodium
Available online on www.ijddt.com International Journal of Drug Delivery Technology 214; (3); 98-13 Research Article ISSN: 97 441 Formulation and In-vitro Evaluation of Chewable Tablets of Montelukast
More informationSCIENTIFIC DISCUSSION. Efavirenz
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredient (API): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
More informationSCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationExcipient Functionality & Pharmacopoeia IPEC Europe Excipients Forum Nice, 5 February 2015
Excipient Functionality & Pharmacopoeia IPEC Europe Excipients Forum Nice, 5 February 2015 Dr. Susanne Keitel Director EDQM, Council of Europe Outline 1. The European Pharmacopoeia 2. The importance of
More informationFAO SPECIFICATIONS FAO PLANT PROTECTION PRODUCTS. ZINEB Zinc ethylenebisdithiocarbamate
AGP: CP/82 FAO SPECIFICATIONS FAO PLANT PROTECTION PRODUCTS ZINEB Zinc ethylenebisdithiocarbamate FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS Rome, 1979 DISCLAIMER 1 FAO specifications are
More informationFood supplement manufacture
Food supplement manufacture Nick Bennett BSc. RNutr April 2018 1 Introduction There are many different product formats available Liquids, powders, tablets, capsules etc Many different types of machine
More informationType 1 Type 2 Type 3 (a) Density at 20 0 C Min (b) Refractive Index at 20 0 C, Min (c)
-COPY OF- INSTRUCTIONS/CLARIFICATIONS/RELEASES Dated 19 th January, 2016 Notice calling for claims, suggestions, views, comments etc from WTO-SPS Committee Members within a period of 60 days on the draft
More informationEP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2009/42
(19) (12) EUROPEAN PATENT APPLICATION (11) EP 2 8 36 A1 (43) Date of publication: 14..09 Bulletin 09/42 (21) Application number: 084239.1 (1) Int Cl.: A61K 9/16 (06.01) A61K 9/ (06.01) A61K 31/4178 (06.01)
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Rifampicin/Isoniazid 150mg/75mg filmcoated Tablets Svizera
More informationSuper Absorbent Polymers (SAPs)
TPP Super Absorbent Polymers (SAPs) A comprehensive range of products that provide comfort and convenience in countless ways SONGWON offers an extensive range of polymers. Solution (thermosetting and/or
More informationShort Communication. Formulation of Furosemide Dispersible Tablets for Use in Paediatrics V. V. ABWOVA, P. N. MBEO, L. J. TIROP AND K. A. M.
61 East and Central African Journal of Pharmaceutical Sciences Vol. 18 (2015) 61-66 Short Communication Formulation of Furosemide Dispersible Tablets for Use in Paediatrics V. V. ABWOVA, P. N. MBEO, L.
More informationThe influence of lactose particle size on dry powder inhalation performance
The influence of lactose particle size on dry powder inhalation performance MCC Starch Lactose Inhalation Superdisintegrants 1 Introduction In most dry powder inhalation (DPI) formulations carriers are
More informationCELLULOSE, MICROCRYSTALLINE. Cellulosum microcristallinum. Cellulose, microcrystalline EUROPEAN PHARMACOPOEIA 7.0
Cellulose, microcrystalline EUROPEAN PHARMACOPOEIA 7.0 Phthaloyl groups (C 8 H 5 O 3 ; M r 149.1): typically 30.0 per cent to 36.0 per cent (anhydrous and acid-free substance). Dissolve 1.000 g in 50 ml
More informationAMENDMENTS TO THE SECOND REVISION OF THE FIRST EDITION OF THE MANUAL ON DEVELOPMENT AND USE OF FAO AND WHO SPECIFICATIONS FOR PESTICIDES
AMENDMENTS TO THE SECOND REVISION OF THE FIRST EDITION OF THE MANUAL ON DEVELOPMENT AND USE OF FAO AND WHO SPECIFICATIONS FOR PESTICIDES Page Current text Revised text Notes P.21 A. 10.1. WHO classification
More informationInternational Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:
Review Article CODEN: IJRPJK ISSN: 2319 9563 International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: www.ijrpns.com ADVANCED GRANULATION TECHNIQUES FOR PHARMACEUTICAL FORMULATIONS
More informationThe Particle Design of Cellulose and the Other Excipients for a Directly Compressible Filler-Binder
The Particle Design of Cellulose and the Other Excipients for a Directly Compressible Filler-Binder Hiroto Miyamoto KNOWKATSU 1 Abstract Cellulose and saccharide are commonly used filler-binder. This summary
More informationBiopharmaceutics Dosage form factors influencing bioavailability Lec:5
Biopharmaceutics Dosage form factors influencing bioavailability Lec:5 Ali Y Ali BSc Pharmacy MSc Industrial Pharmaceutical Sciences Dept. of Pharmaceutics School of Pharmacy University of Sulaimani 09/01/2019
More informationSCIENTIFIC DISCUSSION. Antimycobacterial (J04AC01).
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): International Nonproprietary Name: Pharmaco-therapeutic
More informationCritical material properties for the design of robust drug products : excipient functionality related characteristics
Critical material properties for the design of robust drug products : excipient functionality related characteristics Dr Liz Meehan, Pharmaceutical Development, Macclesfield UK 1 Excipients Definition
More informationExcipient Quality & Trouble Shooting. By Seema Trivedi GM, Technical
Excipient Quality & Trouble Shooting By Seema Trivedi GM, Technical Back Ground The Society for Pharmaceutical Dissolution Science (SPDS) had held its 6th Annual International Convention Disso India -
More informationIngredients adapted to a fit for use model. APIs allowed the fit for use strategy to work. There has been a shift to designed for purpose
1 Pharmaceutical industry borrowed ingredients from other industries Food Cosmetic Industrial Ingredients adapted to a fit for use model. APIs allowed the fit for use strategy to work that has all changed
More informationAbacavir (as sulfate) 300 mg tablets WHOPAR part 6 May 2016 (Hetero Labs Ltd), HA575
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationDESIGN AND EVALUATION OF CONTROLLED RELEASE MATRIX TABLETS OF FLURBIPROFEN
Int. J. Chem. Sci.: 10(4), 2012, 2199-2208 ISSN 0972-768X www.sadgurupublications.com DESIGN AND EVALUATION OF CONTROLLED RELEASE MATRIX TABLETS OF FLURBIPROFEN K. V. R. N. S. RAMESH *, B. HEMA KIRNAMAYI
More informationTo study the effect that hydroxypropylcellulose (HPC) polymer molecular weight (MW) exerts on drug release rates and mechanism from matrix tablets.
PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-029-1 (Supersedes PTR 029) Page 1 of 7 Hydroxypropylcellulose in Modified Release Matrix Systems: Polymer Molecular Weight Controls
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are
More informationResearch Paper The Effect of Different Superdisintegrants and their Concentrations on the Dissolution of Topiramate Immediate Release Tablets
International Journal of Pharmaceutical Sciences and Nanotechnology Volume 2 Issue 2 July September 2009 Research Paper The Effect of Different Superdisintegrants and their Concentrations on the Dissolution
More informationSelenoExcell Food & Beverage Product Guide
SelenoExcell Food & Beverage Product Guide is a high potency (1,200 mcg/g), 100% organically bound selenium yeast product. As a natural nutritional food source, yeast replicates the mineral conversion
More informationTABLET DESIGN AND FORMULATION
TABLET DESIGN AND FORMULATION PART 5 Industrial pharmacy 5th class 1st semester TABLET DESIGN AND FORMULATION Conventional oral tablets for ingestion usually contain the same classes of components in addition
More informationChallenges and solutions for moisture sensitive API formulation
Challenges and solutions for moisture sensitive API formulation Introduction Today, formulators are looking for alternative processes to reformulate existing products or to formulate New Chemical Entities
More informationDesign and development of fast Melting Tablets of Terbutaline Sulphate
Design and development of fast Melting Tablets of Terbutaline Sulphate Mathew T and Agrawal S Swami Vivekanand College of Pharmacy, Khandwa Road, Indore (MP), INDIA Available online at: www.isca.in (Received
More informationAGP:CP/365,1998 SULFOMETURON METHYL. 2-(4,6-dimethylpyrimidin-2-ylcarbamoylsulfamoyl) benzoic acid, methyl ester
AGP:CP/365,1998 SULFOMETURON METHYL 2-(4,6-dimethylpyrimidin-2-ylcarbamoylsulfamoyl) benzoic acid, methyl ester DISCLAIMER 1 FAO specifications are developed with the basic objective of promoting, as far
More informationEXPANDING WHAT S POSSIBLE WITH THE RIGHT PARTNER. Life-saving pharmaceuticals start with high-quality ingredients
EXPANDING WHAT S POSSIBLE WITH THE RIGHT PARTNER Life-saving pharmaceuticals start with high-quality ingredients CONFIDENCE STRAIGHT FROM THE SOURCE From oral dosage excipients (Rx, Gx, nutraceuticals
More informationIJRPC 2012, 2(3) Chowdary et al ISSN: INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article PREPARATION, CHARACTERIZATION AND EVALUATION OF PGS - PVP CO-PROCESSED EXCIPIENT AS DIRECTLY
More information7. SUMMARY, CONCLUSION AND RECOMMENDATIONS
211 7. SUMMARY, CONCLUSION AND RECOMMENDATIONS Drug absorption from the gastro intestinal tract can be limited by various factors with the most common one being poor aqueous solubility and poor permeability
More informationAfrican Journal of Pharmaceutical Research & Development
[Type text] African Journal of Pharmaceutical Research & Development Vol. 7 No.2; pp.101-108 (2015) The Use of Multifunctional Starch Based Coprocessed Excipients (Starac) in the Formulation of Metronidazole
More informationFAO SPECIFICATIONS FAO PLANT PROTECTION PRODUCTS. BROMOPHOS 4-bromo-2,5-dichloropheny1 dimethy1 phosphorothioate
AGP: CP/70 FAO SPECIFICATIONS FAO PLANT PROTECTION PRODUCTS BROMOPHOS 4-bromo-2,5-dichloropheny1 dimethy1 phosphorothioate FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS Rome, 1977 DISCLAIMER
More informationPROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT
Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) Federal Office of Consumer Protection and Food Safety Mauerstraße 39-42 10117 Berlin (Germany) DECENTRALISED PROCEDURE PUBLICLY AVAILABLE
More informationRationale of and Experience with the Expert System
Rationale of and Experience with the Expert System Professor Mitsuru HASHIDA Roland DAUMESNIL Lecture presented during the Controlled Release Society Symposium Optimization of Oral Drug Delivery Hong Kong
More information